PTAB challenges

Proceedings overview

One AIA trial proceeding is currently on file for US Patent 10,064,738, which is in a "Pending" status. This indicates an active challenge against the patent. For a defendant facing assertion of this patent, the patent's claims are currently undergoing review, meaning their validity is not yet confirmed or invalidated by the PTAB.

IPR2026-00265 — Medtronic, Inc. v. Moskowitz Family LLC

• Type: Inter Partes Review
• Filed: 2026-02-20
• Status: Pending. The proceeding is active and awaiting an institution decision or further developments.
• Judge panel: Not yet publicly available in the current status.
• Petition grounds: Not yet publicly available in the current status. The petition would typically challenge specific claims under 35 U.S.C. §§ 102 and/or 103, citing prior art.
• Institution decision: Not yet issued. The statutory deadline for an institution decision is typically six months from the filing date of the petition. For a petition filed on 2026-02-20, the institution decision would be due around 2026-08-20.
• Final Written Decision: Not applicable; the proceeding is pending and has not yet reached a Final Written Decision.
• Settlement / termination: No settlement or termination has been reported; the proceeding remains active.
• Appeal: Not applicable.
• Defensive value: This active IPR signifies that the validity of at least some claims of US 10,064,738 is currently being challenged by Medtronic, Inc. If the PTAB institutes the IPR, it suggests that Medtronic has demonstrated a reasonable likelihood of prevailing on at least one claim, which could weaken the patent owner's position in any ongoing or future litigation. A defendant should monitor this proceeding closely as its outcome will directly impact the strength and scope of the patent.

Strategic summary

As of today, May 29, 2026, all claims of US 10,064,738 are currently UNTESTED by a Final Written Decision from the PTAB. One Inter Partes Review (IPR2026-00265) is pending, challenging the patent's claims. This means there are no claims that have been definitively canceled or sustained by the PTAB.

The estoppel landscape will only begin to form if IPR2026-00265 is instituted. If the PTAB institutes the IPR, Medtronic, Inc. (and its privies) would be estopped from raising in future litigation or other PTAB proceedings any invalidity grounds that were raised or reasonably could have been raised during the IPR. Until then, all prior art grounds remain potentially available for a new petitioner or in district court litigation (subject to other procedural rules). The information provided identifies Medtronic, Inc. as the petitioner, not a defensive aggregator like Unified Patents, for this specific IPR.

Recommended next steps

For a defendant facing assertion of US 10,064,738, the primary recommended next step is to closely monitor IPR2026-00265. The most critical upcoming milestone is the institution decision deadline, which is approximately August 20, 2026. This decision will determine whether the PTAB proceeds with a full review of the challenged claims. Accessing the petition, once public, would also be crucial to understand the specific claims being challenged and the prior art asserted against them.